Risk-Reward Balanced at Alexion - Analyst Blog
February 21 2012 - 11:42AM
Zacks
We continue to have a Neutral recommendation on Alexion
Pharmaceuticals, Inc. (ALXN), with a target price of
$87.00.
Alexion performed impressively in the final quarter of 2011. The
company earned 36 cents in the quarter (on an adjusted basis),
beating the Zacks Consensus Estimate by 7 cents and the year-ago
adjusted earnings by 14 cents per share. Earnings in the quarter
benefited from increased revenues. (Read our full coverage of the
earnings report at Alexion Exits 2011 on a Strong Note).
2011 was a good year for Alexion. During the year, the company
successfully expanded the label of its sole marketed product
Soliris. Soliris is available since 2007 for the treatment of
paroxysmal nocturnal hemoglobinuria, a rare genetic blood disorder
and atypical hemolytic uremic syndrome (aHUS), an ultra-rare
genetic disorder.
In September 2011, the US Food and Drug Administration (FDA)
cleared Soliris for treating children and adults suffering from
aHUS. Soliris was subsequently launched in the US. In November
2011, Soliris was approved for aHUS in the EU.
Alexion is studying Soliris for additional indications as well,
such as acute humoral rejection, myasthenia gravis and STEC-HUS.
Currently, there are no approved treatments for any of these
disorders and the successful development of Soliris for one or more
of these indications will further expand the market potential of
the drug.
We are also encouraged by the company’s strategy of pursuing
acquisitions/signing deals to expand its pipeline beyond Soliris.
The acquisitions of Taligen Therapeutics, Enobia Pharma and the
purchase of the patents and assets from Orphatec Pharmaceuticals
are aimed towards fulfilling this objective. Moreover, the strong
balance sheet gives Alexion the opportunity to make further
acquisitions/deals to develop its pipeline and expand its product
portfolio.
However, the excessive dependence of Alexion on Soliris for
growth concerns us. Failure of the company to develop additional
products will impact the stock price negatively.
Even though pleased with the label expansion of Soliris in the
US and EU for the aHUS indication, we believe that it will take
some time before sales from the additional indication start
contributing meaningfully to the top line. Moreover, we believe
that sales potential will be limited given the small aHUS patient
population.
We prefer to remain on the sidelines until more visibility is
obtained on the commercial potential of Soliris for the aHUS
indication. Consequently, we retain our Neutral stance on the
stock.
ALEXION PHARMA (ALXN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From May 2024 to Jun 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Jun 2023 to Jun 2024